Hepatitis C viral infection increases the risk of lymphoid‐neoplasms: A population‐based cohort study

Tung‐Hung Su, Chun‐Jen Liu, Tai‐Chung Tseng, Shih‐Wan Chou, Chen‐Hua Liu, Hung‐Chih Yang, Shang‐Ju Wu, Pei‐Jer Chen, Ding‐Shinn Chen, Chi‐Ling Chen, Jia‐Horng Kao – 10 December 2015 – Chronic hepatitis C viral (HCV) infection has been associated with non‐Hodgkin's lymphoma (NHL); however, the results are inconsistent among regions with different HCV prevalence rates. The temporal relationship, risk estimates, and association between HCV and lymphoid‐neoplasms remain unclear.

NKp46+ natural killer cells attenuate metabolism‐induced hepatic fibrosis by regulating macrophage activation in mice

Annie‐Carole Tosello‐Trampont, Peter Krueger, Sowmya Narayanan, Susan G. Landes, Norbert Leitinger, Young S. Hahn – 10 December 2015 – Nonalcoholic steatohepatitis (NASH) affects 3%‐5% of the U.S. population, having severe clinical complications to the development of fibrosis and end‐stage liver diseases, such as cirrhosis and hepatocellular carcinoma. A critical cause of NASH is chronic systemic inflammation promoted by innate immune cells, such as liver macrophages (Mϕ) and natural killer (NK) cells.

Noninvasive fatty liver markers predict liver disease mortality in the U.S. population

Aynur Unalp‐Arida, Constance E. Ruhl – 10 December 2015 – Nonalcoholic fatty liver disease (NAFLD) contributes to premature death along with obesity, diabetes, and cardiovascular disease (CVD). We examined whether hepatic steatosis (HS) on ultrasound and liver enzyme activities were associated with increased liver disease mortality in the U.S. National Health and Nutrition Examination Survey (NHANES), 1988‐1994, with up to 23 years of linked‐mortality data.

Subscribe to